Biostatistics Shared Resource Office Hours!.ppt

1、Biostatistics Shared Resource Office Hours!,Yale Cancer Center offers biostatistics and bioinformatics support to all members/projects through the Biostatistics Shared Resource (BSR), which is led by Dr. Shuangge (Steven) Ma. Dr. Ma has over ten years of experience conducting cancer biostatistical r

2、esearch, including serving as co-director of the Biostatistics and Bioinformatics Core of the Yale SPORE in Skin Cancer, and is also the senior genetic statistician for the VA CT Healthcare System. YCC members are eligible to receive up to 16 hours per year of service at no cost. As funding agencies

3、 and journals continue to place increasing emphasis on proper analytics, it is critical to involve statisticians early on and in all stages of your study. Whenever you have a new project or idea, Dr. Ma urges you to contact him (shuangge.mayale.edu) and he will introduce you to the appropriate facul

4、ty or staff at the BSR so that you can take advantage of their expertise and your YCC member benefit.The BSR is happy to re-announce its drop-in consultation service. Dr. Wei Wei, an experienced statistician with special expertise in clinical trial design and analysis and general analytics, provides

5、 on-site biostatistics support. Drs. Yong Kong and Ying Zhu, both with extensive experience in the analysis of genetic, genomic, proteomic, and epigenetic data, provide bioinformatics support.Biostatistics Shared Resource (BSR) Drop-In Office Hours - WWW213Biostatistics Dr. Wei Wei Thursdays - 9am-1

6、pm Fridays - 9am-5pmBioinformatics Drs. Yong Kong and Ying Zhu Fridays - 1pm-5pm,Member Notables,Stand Up To Cancer recently announced a new Convergence Research Program, which will use artificial intelligence to investigate immunotherapies. As part of their new program, two Yale Cancer Center resea

7、rchers were awarded grants. Rong Fan, PhD, a member of our Signal Transduction Research Program, will lead the project, “Single-Cell Functional Multi-Omics to Characterize and Monitor CAR T Therapy.“ Alessandro Santin, MD, a member of our Developmental Therapeutics Research Program, will lead, “Resp

8、onders and Non-responders to Endometrial Cancers with Mismatch Repair.“ Learn More Jason Crawford, PhD, a member of Yale Cancer Centers Developmental Therapeutics Research Program, has been named the Maxine F. Singer 57 PhD Associate Professor of Chemistry and of Microbial Pathogenesis.,Member Notab

9、les,Steven Gore is one of the regular hosts of Yale Cancer Answers,Member Notables,Roy Herbst - SWOG Cancer Research Leader,Member Notables,Amer Zeidan speaking at the 2018 International Conference of the Jordanian Society of Hematology,Member Notables,Brian Shuch discusses the genetics of kidney ca

10、ncer and how this can plan into treatment methods on Yale Cancer Answers.,Member Notables,Co-Director Lieping Chen (CI) and Interim Co-Director Roy Herbst (DT),Funding Opportunities Comprehensive List check here: http:/yalecancercenter.org/research/foa.aspx,SPORE in Lung Cancer Program Awards: Caree

11、r Development Program The Career Development Program will provide support of up to $50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research. Application Timeline: Letters of intent (LOI) are due no later than 5:00 PM, Apr

12、il 27, 2018 Learn More SPORE in Lung Cancer Program Awards: Developmental Research Program To provide seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated into, a full Yale SPORE in Lung Cancer project. Applic

13、ation Timeline: Letters of intent are due no later than 5:00 PM, April 27, 2018 Learn More ,Funding Opportunities Comprehensive List check here: http:/yalecancercenter.org/research/foa.aspx,2018 YCC Internal Pilot GrantsThese grants will support innovative basic, clinical, population, computational,

14、 prevention/control, and translational cancer research. The primary review criteria will be scientific excellence, innovation, cancer relevance, and the likelihood of the project evolving into federally funded cancer research. Members of Yale Cancer Center or faculty who have applied for membership

15、are eligible to apply. The anticipated start date is May 1, 2018.Projects headed by a member of Yale Cancer Center will be awarded up to $50,000. YCC Program Leaders may not apply for pilot funding. We welcome all potential areas of cancer research, recognizing the following funding priorities: Micr

16、obiome, including its role in carcinogenesis and modulation of cancer therapy Single cell analysis to understand tumor heterogeneity, microenvironment, tumor immune response Undruggable targets, including immunotherapeutic, novel delivery approaches, or synthetic lethal approaches DNA repair and the

17、rapeutics Metabolic dysregulation in cancerIn addition, applications that incorporate studies of underserved populations or novel data science and computational approaches will receive greater funding priority. Submission deadline is 11:59pm on April 2nd, 2018. Grant guidelines and electronic applic

18、ation instructions can be obtained on Submittable (https:/ scientific questions, please contact joann.sweasyyale.edu. All other inquiries should be sent to christine.holmbergyale.edu.,Upcoming Events - https:/medicine.yale.edu/cancer/patient/calendar/,YCC Annual Retreat May 16th West Campus Conferen

19、ce Center Agenda TBD YCC Grand Rounds Most Tuesdays 12-1pm 55 Park Street Auditorium Speaker TBD Now viewable on Skype! Find out how on the calendar posting at the link above Next DT Seminar is April 20th - Speaker TBD,Yale Dept of Urology Hosts: Mens Health Symposium: “Mens Health Across the Lifesp

20、an” with David Shin and Alexander Pastuszak March 17 7-1pm 2 Bridge St, Old Saybrook Radiobiology & Radiotherapy (RR) Research Program Seminar March 19 11-12pm, SHM I-304 Timothy Nottoli: “Creating Mouse Models with the Yale Genome Editing Center” and “A DNA Repair Variant and Lupus” Cancer Preventi

21、on and Control (CPC) Research Program Seminar March 28 - 12-1pm Fitkin Rm 304 Michael Leapman: ”New Paradigms for Low Risk Prostate Cancer: Can Better Predictions Lead to Better Outcomes?”,February Publications Please note: These have not been reviewed for cancer relevance yet.,A Phase I Dose-Escala

22、tion Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. Foss FM, Parker T Oncologist E publication ahead of print: (02/2018) PM ID: 29438091 Associated characteristics and impact on recurrence and survival of free-floating tumor fr

23、agments in the lumen of fallopian tubes in Type I and Type II endometrial cancer. Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P,Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE Gynecol Oncol Rep 23: 28-33 (02/2018) PM ID: 29387776 P

24、MC5771964 DNA Repair: Unconventional Lesions Require Unconventional Repair. Herzon SB Biochemistry 57: 1057-1058 (02/2018) PM ID: 29406697,*/*,*/* - Indicates Intra- and Inter-programmatic collaboration,February Publications,Endothelial Cell Autonomous Role of Akt1: Regulation of Vascular Tone and I

25、schemia-Induced Arteriogenesis. Lee MY, Gamez-Mendez A, Zhang J, Zhuang Z, Vinyard DJ, Kraehling J, Velazquez H, Brudvig GW, Kyriakides TR, Simons M, Sessa WC Arterioscler Thromb Vasc Biol E publication ahead of print: (02/2018) PM ID: 29449333 Erythema Nodosum-like Eruption in the Setting of Sorafe

26、nib Therapy. Coleman EL, Cowper SE, Stein SM, Leventhal JS JAMA Dermatol E publication ahead of print: (02/2018) PM ID: 29453869 In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers. Altwerg

27、er G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD Mol Cancer Ther : (02/2018) PM ID: 2

28、9440294 Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Shallis RM, Zeidan AM Leuk Lymphoma : 1-3 (02/2018) PM ID: 29411698,*/*,*/* - Indicate Intra- and Inter-programmatic collaboration,February Publications,Microbiota-Regulated Ou

29、tcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis. Patel J, Crawford JM Biochemistry 57: 901-903 (02/2018) PM ID: 29350031 Mirror Movements in a Patient With Brain Tumor. Kaulen LD, Baehring JM JAMA Neurol E publication ahead of print: (02/2018) PM ID: 29435583 More is less, less is more,

30、 or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. Shallis RM, Zeidan AM BMC Hematol 18: 4 (02/2018) PM ID: 29435332 PMC5796398 MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and D

31、ata System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. Sheridan AD, Nath SK, Aneja S, Syed JS, Pahade J, Mathur M, Sprenkle P, Weinreb JC, Spektor M AJR Am J Roentgenol E publication ahead of print: W1-W8 (02/2018) PM ID: 29489409,February Publications,Patients

32、 treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Curtis BR, Hsu YS, Podoltsev N, Lacy J, Curtis S, Samuel MS, Zutavern K, DeSimone RA, Bougie DW, Aster RH Blood E publication ahead of print: (02/2018) PM ID: 29439950 The optimal timing of Hepat

33、itis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities. Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M, European Liver and Intestine Transplant Association (ELITA) J Viral Hep

34、at E publication ahead of print: (02/2018) PM ID: 29406608 Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base. Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL Cancer 124: 717-726 (0

35、2/2018) PM ID: 29243245 Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level. Charkoftaki G, Rattray NJW, Andrn PE, Caprioli RM, Castellino S, Duncan MW, Goodwin RJA, Schey KL, Shahidi-Latham SK, Veselkov KA, Johnson CH, Vasiliou V Hum Genomics 12: 10 (02/2018) PM ID: 29482659 PMC5828306,*,* - Indicates Intra-programmatic collaboration * - Indicated Inter-programmatic collaboration,*,*,Did I miss your good news?Email: christina.dreyfusyale.edu by March 30th for Aprils seminar,